Already offering the only non-invasive treatment for SMA in liquid form, Roche’s Evrysdi now comes as a tablet.

Cost-effectiveness body NICE has rejected Biogen’s Spinraza (nusinersen) therapy for the rare genetic muscle wasting disease spinal muscular atrophy (SMA) because of its high cost – but is in ...

and Tysabri (natalizumab), as well as blockbuster spinal muscular atrophy therapy Spinraza (nusinersen). Biogen will retain its commercial rights to the biosimilars already brought to market ...

Spinraza (nusinersen) treatment helped school-age children with SMA be more independent in tasks involving their arms and ...

MRI imaging scans can track muscle changes in SMA children given Spinraza, a study found, with better results seen with early ...

The global Oligonucleotide Synthesis Market, valued at US$8.9 billion in 2024 stood at US$10.5 billion in 2025 and is projected to advance at ...

Biogen appointed multiple co-lead underwriters for two fixed-income offerings totaling over $1 billion, showcasing its efforts to bolster financial offerings. This move, coupled with Biogen's ...

Biogen will open a West Coast hub in South San Francisco after acquiring a Peninsula drugmaker. The Massachusetts-based biotech firm plans to set up shop in an undisclosed office in South San ...

On Thursday, Goldman Sachs reaffirmed its confidence in Biogen (NASDAQ: BIIB) shares, maintaining a Buy rating and a price target of $196.00.According to InvestingPro data, Biogen currently trades ...

TOKYO -- Japan's Eisai and American partner Biogen will transfer some production of active ingredients for their Alzheimer's disease treatment lecanemab to the U.S. amid concerns that President ...